Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry

This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1 percent increase in the potential market size for a drug category leads to a 4 to 6 percent increase in the number of new drugs in that category. This response comes from both the entry of generic drugs and new non-generic drugs, and is generally robust to controlling for a variety of non-profit factors, pre-existing trends

[1]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[2]  Paul A. Samuelson,et al.  A Theory of Induced Innovation along Kennedy-Weisacker Lines , 1965 .

[3]  Jeffrey M. Woodbridge.  Econometric Analysis of Cross Section and Panel Data , 2002 .

[4]  E. Drandakis,et al.  A Model of Induced Invention, Growth and Distribution , 1966 .

[5]  Vernon W. Ruttan,et al.  Factor Prices and Technical Change in Agricultural Development: The United States and Japan, 1880-1960 , 1970, Journal of Political Economy.

[6]  J. Mill.  Principles of Political Economy , 2011, Forerunners of Realizable Values Accounting in Financial Reporting.

[7]  Paul E. Ceruzzi,et al.  A history of modern computing , 1999 .

[8]  G. Grossman,et al.  Innovation and growth in the global economy , 1993 .

[9]  R. Blundell,et al.  Initial Conditions and Moment Restrictions in Dynamic Panel Data Models , 1998 .

[10]  J. Wooldridge.  Distribution-free estimation of some nonlinear panel data models , 1999 .

[11]  Z. Griliches,et al.  Econometric Models for Count Data with an Application to the Patents-R&D Relationship , 1984 .

[12]  D. Acemoglu.  Labor- and Capital- Augmenting Technical Change , 2000 .

[13]  Franco Malerba,et al.  Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a history‐friendly model , 2002 .

[14]  David E. Nye,et al.  Electrifying America: Social Meanings of a New Technology , 1992 .

[15]  Frederic M. Scherer,et al.  Innovation and growth , 1984 .

[16]  Jeffrey M. Wooldridge,et al.  Solutions Manual and Supplementary Materials for Econometric Analysis of Cross Section and Panel Data , 2003 .

[17]  F. Lichtenberg,et al.  Does Misery Love Company? Evidence from Pharmaceutical Markets Before and after the Orphan Drug Act , 2003 .

[18]  F. Lichtenberg.  The Allocation of Publicly-Funded Biomedical Research , 1997 .

[19]  Amy N. Finkelstein.  Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry , 2004 .

[20]  F. Lichtenberg.  The Effects of Medicare on Health Care Utilization and Outcomes , 2002 .

[21]  Scott Stern,et al.  The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research , 1999 .

[22]  D. Acemoglu.  Directed Technical Change , 2001 .

[23]  M. Arellano,et al.  Another look at the instrumental variable estimation of error-components models , 1995 .

[24]  Louis Galambos,et al.  Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation , 1998, Business History Review.

[25]  A. Jaffe,et al.  The Induced Innovation Hypothesis and Energy-Saving Technological Change , 1998 .

[26]  Bart Verspagen,et al.  Patents, citations, and innovations , 2004 .

[27]  D. Acemoglu.  Why Do New Technologies Complement Skills? Directed Technical Change and Wage Inequality , 1998 .

[28]  David O. Meltzer,et al.  Do Important Drugs Reach the Market Sooner , 1994 .

[29]  Z. Griliches,et al.  Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs , 1997 .

[30]  Daron Acemoglu.  Directed Technical Change , 2002 .

[31]  F. Lichtenberg.  The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001 , 2003, International Journal of Health Care Finance and Economics.

[32]  D. Acemoglu,et al.  Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry , 2003 .

[33]  Syed Ahmad,et al.  On the Theory of Induced Invention , 1966 .

[34]  F. Morton,et al.  Entry decisions in the generic pharmaceutical industry. , 1999, The Rand journal of economics.

[35]  P. Romer.  Endogenous Technological Change , 1989, Journal of Political Economy.

[36]  I. Cockburn,et al.  Scale, scope, and spillovers: the determinants of research productivity in drug discovery. , 1996, The Rand journal of economics.

[37]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[38]  B. Spilker,et al.  Science and Innovation: The US Pharmaceutical Industry During the 1980s , 1996 .

[39]  Michael R. Ward,et al.  Generic Drug Industry Dynamics , 2002, Review of Economics and Statistics.

[40]  David Popp,et al.  Induced Innovation and Energy Prices , 2001 .

[41]  Stefano DellaVigna,et al.  Attention, Demographics, and the Stock Market , 2005 .

[42]  I. Cockburn,et al.  Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. , 2001, Journal of health economics.

[43]  N. Rosenberg.  Science, Invention and Economic Growth , 1974 .

[44]  Paul A. David,et al.  Technical Choice Innovation and Economic Growth: Essays on American and British Experience in the Nineteenth Century , 1975 .

[45]  Zvi Griliches,et al.  Patents and R&D at the firm level: A first report , 1980 .

[46]  Jacob Schmookler,et al.  Invention and Economic Growth , 1967 .

[47]  Michael Kremer,et al.  Pharmaceuticals and the developing world. , 2002, The journal of economic perspectives : a journal of the American Economic Association.

[48]  A. Pakes,et al.  Patents and R&D at the Firm Level: A First Look , 1984 .

[49]  Z. Griliches.  HYBRID CORN: AN EXPLORATION IN THE ECONOMIC OF TECHNOLOGICAL CHANGE , 1957 .

[50]  F. Lichtenberg.  Sources of U.S. Longevity Increase, 1960 - 1997 , 2000, SSRN Electronic Journal.

[51]  Ariel Pakes,et al.  An Exploration into the Determinants of Research Intensity , 1980 .

[52]  P. Howitt,et al.  Endogenous Growth Theory , 1999 .

[53]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[54]  R. Cerda.  LABOR MARKET AND UNEMPLOYMENT , 2003 .

[55]  C. Kennedy,et al.  Induced Bias in Innovation and the Theory of Distribution , 1964 .

[56]  R. Cerda.  Drugs, market size and population. , 2003 .